Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Vipul S Sheth"'
Publikováno v:
Frontiers in Pediatrics, Vol 8 (2020)
Minor Histocompatibility (H) antigens are major histocompatibility complex (MHC)/Human Leukocyte Antigen (HLA)-bound peptides that differ between allogeneic hematopoietic stem cell transplantation (HCT) recipients and their donors as a result of gene
Externí odkaz:
https://doaj.org/article/37039864fddf445e856974d2baa770f3
Autor:
Shaowei Qiu, Vipul S Sheth, Chengcheng Yan, Juan Liu, Balu K. Chacko, Hui Li, David K. Crossman, Seth D. Fortmann, Sajesan Aryal, Ashley Rennhack, Maria B. Grant, Robert S. Welner, Andrew J. Paterson, Adam R. Wende, Victor M. Darley-Usmar, Rui Lu, Jason W. Locasale, Ravi Bhatia
Publikováno v:
Blood Journal.
Tyrosine kinase inhibitors (TKI) are very effective in treating chronic myelogenous leukemia (CML), but primitive, quiescent leukemia stem cells persist as a barrier to cure. We performed a comprehensive evaluation of metabolic adaptation to TKI trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5b2b7f28df7228a8b693ae82067a87a
https://doi.org/10.1182/blood.2022018196
https://doi.org/10.1182/blood.2022018196
Autor:
Ghulam J. Mufti, Victoria T Potter, Shreyans Gandhi, Vipul S Sheth, Donal Mclornan, Antonio Pagliuca, Austin G. Kulasekararaj, K Raj, Varun Mehra, Francesco Dazzi, Hugues de Lavallade, Pramila Krishnamurthy
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-6 (2021)
Blood Cancer Journal
Blood Cancer Journal
Pre-emptive DLI (pDLI) is an effective strategy in lowering the risk of relapse without significantly increasing the risk of graft-versus-host disease (GVHD) in the case of T cell lineage mixed chimerism (MC) post allogeneic transplant in hematologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7135de18c003bd496c69dd43ad734d35
https://doi.org/10.1038/s41408-021-00519-y
https://doi.org/10.1038/s41408-021-00519-y
Autor:
Jordan Gauthier, Vipul S Sheth
Publikováno v:
Bone Marrow Transplant
Treatment with CD19 or CD22-targeted chimeric antigen receptor-engineered T (CD19/CD22 CAR-T) cells achieve complete responses in approximately 60 to 90% of adults and children with refractory or relapsed (R/R) acute lymphoblastic leukemia (ALL). Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f03b41643de8e884a93e7b04d1c2b4c0
https://pubmed.ncbi.nlm.nih.gov/33230186
https://pubmed.ncbi.nlm.nih.gov/33230186
Publikováno v:
Frontiers in Pediatrics, Vol 8 (2020)
Frontiers in Pediatrics
Frontiers in Pediatrics
Minor Histocompatibility (H) antigens are major histocompatibility complex (MHC)/Human Leukocyte Antigen (HLA)-bound peptides that differ between allogeneic hematopoietic stem cell transplantation (HCT) recipients and their donors as a result of gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c01dcfc90711db9e73a02664a9865feb
https://doi.org/10.3389/fped.2020.00284
https://doi.org/10.3389/fped.2020.00284
Publikováno v:
JCI Insight
Protection from relapse after allogeneic hematopoietic cell transplantation (HCT) is partly due to donor T cell-mediated graft-versus-leukemia (GVL) immune responses. Relapse remains common in HCT recipients, but strategies to augment GVL could signi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e26b4b2c2aa1d32eb9711133ae9180ec
https://doi.org/10.1172/jci.insight.134939
https://doi.org/10.1172/jci.insight.134939